Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3939 studies found for:    novartis
Show Display Options
Download search resultsDownload the search results for:
novartis (3939 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Active, not recruiting Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative
Conditions: Cardiovascular Disease;   Diabetes Type II;   Breast Cancer;   Asthma
Intervention: Other: Novartis Access
2 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Conditions: Meningococcal Infections;   Meningococcal Meningitis
Interventions: Biological: MenACWY CRM;   Biological: Meningococcal ACWY Conjugate vaccine
3 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
Conditions: Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal ACWY Polysaccharide Vaccine;   Biological: MenACWY CRM (19 to 55 years);   Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: Novartis MenACWY Vaccine (56 to 65 Years)
4 Unknown  Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers
Condition: Bacterial Colonization
Interventions: Drug: Lactitol;   Drug: Lactobacillus
5 Recruiting Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus;   Drug: Sandostatin LAR Depot
6 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
Conditions: Meningococcal Meningitis;   Human Papillomavirus Infection;   Pertussis;   Tetanus
Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine;   Biological: Tdap Vaccine
7 Completed
Has Results
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM;   Biological: Licensed meningococcal ACWY vaccine
8 Completed Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Condition: Neoplasms
Intervention: Drug: Everolimus
9 Active, not recruiting Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: nilotinib
10 Completed Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
Condition: Healthy
Intervention: Drug: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
11 Completed Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Condition: Healthy
Interventions: Drug: CJ Amlodipine/Valsartan 10/160mg;   Drug: Novartis Exforge 10/160mg
12 Completed
Has Results
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: MenC-CRM LIQ;   Biological: MenC-CRM ROS;   Biological: MenC-CRM EMV
13 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease;   Acromegaly;   Neuroendocrine Tumors;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors;   Dumping Syndrome;   Prostate Cancer;   Melanoma Negative for bRAF;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
14 Completed
Has Results
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal B Recombinant vaccine rMenB+OMV NZ;   Biological: Placebo;   Biological: Meningococcal ACWY-CRM conjugate vaccine
15 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Condition: Influenza
Intervention: Other: Non-intervention observational study
16 Active, not recruiting Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinant vaccine together with routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age);   Biological: Routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
17 Completed
Has Results
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib-IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
18 Completed
Has Results
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
Condition: Meningococcal Disease
Interventions: Biological: Men ACWY CRM;   Biological: 4CMenB
19 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
20 Active, not recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.